ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results
July 12 2018 - 4:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Company will host a conference call at 8:00
a.m. ET on Friday, July 27, 2018 to discuss its second quarter
operating results. Management will also provide a brief update on
the business.
Conference Call InformationTo access the live call by
phone, dial 719-785-1753; the conference ID is 2275763. The call
may also be accessed through the Investors section of the Company’s
website, www.immunogen.com. Following the webcast, a replay of the
call will be available at the same location through August 10,
2018.
About ImmunoGenImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” Our
lead product candidate, mirvetuximab soravtansine, is in Phase 3
study for folate receptor alpha (FRα)-positive platinum resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens.
Our novel IGN candidates for hematologic malignancies, IMGN779 and
IMGN632, are in Phase 1 studies. Learn more about who we are, what
we do, and how we do it at www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180712005760/en/
INVESTOR RELATIONS CONTACTImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMEDIA CONTACTCourtney
O’Konek, 781-895-0600courtney.okonek@immunogen.comorFTI
ConsultingRobert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024